Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Nichi-Iko Starting Marketing Operations from March 29
March 29, 2021
- LDP Group to Submit Request for HPV Vaccine Promotion Resumption
March 26, 2021
- Chuikyo to Compile Reimbursement Rule for Therapeutic Apps by Year-End
March 25, 2021
- Chuikyo Members Rail against Generic Manufacturing Scandals
March 25, 2021
- Chuikyo OKs Appraisal Results for Kymriah, Trelegy; Downward Price Tweaks Expected
March 25, 2021
- 6.1% of Hospitals Have Established Formularies: Chuikyo Survey
March 25, 2021
- Nichi-Iko Plant Probed before Lifting of Biz Suspension Order
March 25, 2021
- MHLW Notifies of Guidelines on Use of Registry Data in Regulatory Submissions
March 25, 2021
- Toyama Govt to Probe Repeated Failures to Discover Nichi-Iko’s GMP Violations
March 25, 2021
- Japan Approves Incyte’s Pemazyre, Bayer’s Vitrakvi, Novartis’ Kesimpta, and More
March 24, 2021
- Incidence of Post-Vaccine Anaphylaxis in Japan Comparable with US: MHLW
March 23, 2021
- Appraisal Results for Kymriah, Trelegy Up for Chuikyo Review on March 24; Price Cuts Likely
March 23, 2021
- COVID-19 Vaccines to Be Shipped with 6-Dose Syringes from Week of April 12, for Use in 2nd-in-Line HCPs
March 23, 2021
- Govt Disclosing Suspected Vaccine Reactions Less Frequently after Expert Advice: Minister
March 22, 2021
- MHLW Panel Hails Use of Clinical Research Data for Regulatory Submissions, but Wants Requirements to Ensure Safety
March 22, 2021
- MHLW to Set Up Medical Supply Office in April after COVID-19, Antibiotic Shortage
March 19, 2021
- Japan to Boost Screening of Coronavirus Variants: Minister
March 19, 2021
- Japan IP High Court Snubs Ex-Grad Student's Appeal over Opdivo Patent Claim
March 19, 2021
- Monitoring Panel to Require MHLW's Periodic Reports on Products Designated for Sakigake Review, Conditional Early Approval
March 18, 2021
- MHLW to Continue Looking into Cause of Generic Scandals: Minister
March 17, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…